Empire Metals, Caledonia Mining, Quantum Helium, Great Southern Copper, Quadrise, Futura Medical

Why It Matters

The announcements signal that several small‑cap firms are moving from discovery to commercial execution, offering investors high‑growth exposure across critical commodities and health‑tech markets.

Key Takeaways

• Empire Metals targets ASX listing after confirming 2.2 bn‑ton titanium resource.
• Caledonia Mining’s profit triples to $67.5 m, aims multi‑mine expansion.
• Quantum Helium generates $600k oil revenue, funding helium production tests.
• Great Southern Copper hits mineralization across all Cerro Negro holes, plans Phase 4.
• Futura Medical’s ED gel shows 84% success; FDA filing for stronger version.

Summary

The Proactive roundup highlighted six small‑cap miners and tech firms that posted notable milestones this week. Empire Metals confirmed a 2.2 billion‑ton titanium deposit in Western Australia and is gearing up for a scoping study and potential ASX listing. Caledonia Mining reported a near‑tripling of profit to $67.5 million, driven by higher gold prices, and outlined a 2026 strategy to become a multi‑mine producer. Quantum Helium leveraged $600,000 of oil sales from its Sagebrush project in Colorado to fund helium production tests, while Great Southern Copper announced consistent mineralization across all drill holes at Cerro Negro, Chile, and is preparing Phase 4 drilling.

The companies also disclosed concrete operational progress. Empire Metals will focus on drilling and a definitive feasibility study; Caledonia’s free cash flow rose to $62 million, underscoring strong balance‑sheet health. Quantum Helium’s extended production test at Sagebrush One aims to validate commercial helium output, and Great Southern Copper’s high‑grade silver extension now stretches 1.5 km south of the Mustaza mine. Quadrise, though not a primary focus, increased cash to £4 million to support MSC fuel‑trial sign‑offs in Morocco. Futura Medical reported that its Roxxon ED gel delivered erections lasting long enough in 84% of cases, prompting an FDA filing for an enhanced formulation, Eroxon Intense.

These updates illustrate a broader trend of small‑cap firms accelerating toward commercial milestones and market listings. The mix of resource confirmation, profit surges, and clinical trial successes signals heightened investor interest and potential capital inflows, especially as each company positions itself for near‑term growth.

For investors, the news underscores opportunities in niche sectors—titanium mining, gold production, helium extraction, high‑grade copper‑silver projects, and medical devices—where early‑stage companies are transitioning from exploration or development to revenue‑generating operations, potentially delivering outsized returns if milestones are met.

Original Description

Empire Metals (AIM:EEE, OTCQX:EPMLF) has wrapped up a big year in 2025, confirming one of the world's largest titanium resources at 2.2 billion tonnes in Western Australia. This year it's all about drilling, a scoping study, and a possible ASX listing.

Caledonia Mining (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) has had a cracking year — profit nearly tripled to $67.5 million as gold prices did the heavy lifting. Free cash flow jumped to $62 million, and the focus for 2026 is becoming a multi-mine producer.

Quantum Helium (AIM:QHE) pulled in over $600,000 in oil sales last year from its Sagebrush Project in Colorado, helping fund its helium ambitions. Production is holding steady into 2026, and the big near-term moment is an extended production test at Sagebrush-1.

Great Southern Copper (LSE:GSCU, FRA:E9E) has hit mineralisation in every hole at Cerro Negro in Chile, extending high-grade silver results 1.5 kilometres south of the Mostaza mine. Phase IV drilling is already being prepped, with more targets still untested.

Quadrise (AIM:QED) is pushing hard to get vessel trials signed off with MSC and fuel trials moving in Morocco. Cash on the balance sheet has grown to £4 million, giving it runway to get those commercial milestones over the line.

Futura Medical (AIM:FUM, OTC:FAMDF, FRA:GYX) has strong trial results for its Eroxon ED gel, with erections lasting long enough in 84% of encounters. A new stronger version, Eroxon Intense, is already filed for FDA approval and expected to land in the first half of this year.

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.